Dercum’s Disease Market is predicted to reach USD 22.75 billion at a CAGR of 6.76% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Dercum’s Disease Market”.

Dercum’s disease market is estimated to register a CAGR of 6.76% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global dercum’s disease market— IBM (US), Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland).

Market Highlights

The global dercum’s disease market is accounted to register a CAGR of 6.76% during the forecast period and is estimated to reach USD 22.75 billion by 2032.

Increasing pipeline studies to develop medication, surgery, liposuction, and electrotherapy are expected to drive the global dercum’s disease market growth over the forecast period. For instance, in September 2020, Raziel Therapeutics, a pharmaceutical company developed RZL-012, an injectable treatment for aesthetics and fat disorders. RZL-012 is a novel synthetic small molecule that kills fat cells when injected into subcutaneous fat. It is the first and only injectable drug that significantly and sustainably shrinks Lipomas' size in dercum's disease, reducing abdominal fat volume and submental fullness. Moreover, increasing product approvals by the regulatory authority are also expected to drive the growth of the dercum’s disease market.

The rising prevalence of rare diseases and increasing research and development activities are propelling the market growth. However, the lack of awareness among the people about the disease is expected to hamper the growth of the global market. Nevertheless, a rising number of strategic initiatives are projected to create lucrative opportunities for market players.

Segment Analysis

The global dercum’s disease market has been segmented based on treatment, end user, and distribution channel.

On the basis of treatment, the market is segmented into surgery, medication, liposuction, electrotherapy, acupuncture, and others. The medication segment is further sub segmented to diuretics, non-steroidal anti-inflammatory drug, corticosteroids, and others. The surgery segment was attributed to holding the largest market share of 31.15% in 2022 revenue as estimated by MRFR analysts. This is due to the rising number of cases of decrum's disease surgeries.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product launches

Based on end user, the global dercum’s disease market has been segmented into hospital & clinics, ambulatory surgical centers, and others. The hospital & clinics segment was expected to hold the largest market share in 2022.

On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is projected to have the largest market share during the forecast period.

Regional Analysis

The global dercum’s disease market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe dercum’s disease market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The dercum’s disease market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s dercum’s disease market comprises of Middle East, Africa, and Latin America.

the rising government regulatory acts and favorable policies for rare diseases and approval of drug are also expected to foster North America’s market growth.

Moreover, the Europe market has been persistently growing owing to a research study through healthcare regulatory bodies for the treatment of dercum’s disease and favorable policy and public affairs strategies.

Additionally, market factors, such as the increasing approval of dercum’s disease drug products, and sponsored research for clinical trial studies in the region in the Asia-Pacific region and are driving the region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of dercum’s disease market in the region are the lack of awareness about the disease and its management, raising funds, and expansion of companies.

Key Findings of the Study

• The global dercum’s disease market is expected to reach USD 22.75 billion by 2032, at a CAGR of 6.76% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the increasing investment, clinical trial studies, and companies' R&D for drugs to treat adipose dolorosa in the Asia-Pacific region.


• Based on treatment, the surgery segment was attributed to holding the largest market in 2022, with an approximate market share of 31.15%


• Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland) are the key market players.